Grannus Therapeutics

Overview

Grannus Therapeutics is a pre-clinical biotechnology company developing next-generation targeted cancer therapies. Spun out of the University of Notre Dame, the firm focuses on engineering highly selective inhibitors of the Hsp90β (Heat Shock Protein 90 beta) isoform to treat ovarian and other cancers without the toxicity associated with traditional pan-inhibitors.

Key Facts

Sector

Healthcare

Business model

Manufacturing

Stage

Pre-Revenue

Team size

1-10

Focus Areas